Jennerex, Inc.
One Market Street
Spear Tower, Suite 2260
San Francisco
California
94105
United States
Tel: 415-281-8886
Website: http://www.jennerex.com/
Email: info@jennerex.com
69 articles about Jennerex, Inc.
-
SillaJen Biotherapeutics Announces Completion Of Name Change Following Acquisition Of Jennerex, Inc.
6/19/2014
-
SillaJen Grabs Jennerex, Inc. for $150 Million
11/26/2013
-
Jennerex, Inc. Announces That Its Phase 2 Study of Pexa-Vec in Second-Line Advanced Liver Cancer Did Not Meet Its Primary Endpoint
9/4/2013
-
Jennerex, Inc. to Present at the 33rd Annual Canaccord Genuity Growth Conference
8/12/2013
-
TRANSGENE Announces a Follow-on Investment in Jennerex, Inc.
5/28/2013
-
Jennerex, Inc. Completes $21.6 Million Private Placement
5/23/2013
-
Jennerex, Inc. Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
5/21/2013
-
Jennerex, Inc. Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-Cancer Immunity in Patients With Diverse Tumor Types
5/16/2013
-
Jennerex, Inc. Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
5/9/2013
-
Jennerex, Inc. Announces Presentation of Data Demonstrating Pexa-Vec's Vascular Targeting Mechanism
4/9/2013
-
Liver Cancer Survival Time Tripled by Virus, Jennerex, Inc. Reveals
2/13/2013
-
Genetically Engineered Virus Kills Liver Cancer, Jennerex, Inc. Reveals
2/12/2013
-
Jennerex, Inc. Announces Nature Medicine Publication Highlighting Randomized Overall Survival Benefit of Lead Product Candidate, Pexa-Vec (JX-594) in Patients With Advanced Hepatocellular Carcinoma (HCC)
2/11/2013
-
Jennerex, Inc. Announces Cancer Research Publication Demonstrating Vascular Targeting Mechanism of Action of Lead Product Candidate, Pexa-Vec (JX-594)
2/11/2013
-
Jennerex, Inc.'s Drug Candidate, JX-929, Named as One of the Top 10 Oncology Projects to Watch
11/28/2012
-
Jennerex, Inc. Presents Positive Phase 2 Trial of JX-594
9/17/2012
-
Jennerex, Inc. Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
7/25/2012
-
Jennerex, Inc. Appoints Dr. Laurent Fischer as President and Chief Executive Officer
6/28/2012
-
Jennerex, Inc. Presents JX-594 Clinical Data at 2012 American Society of Clinical Oncology Annual Meeting
6/4/2012
-
Jennerex, Inc. Announces Data Presentations Relating to Oncolytic Virus JX-594 at American Society of Clinical Oncology Annual Meeting
5/17/2012